HTBX Gains Momentum, DOVA Faces FDA In May, No Stopping CHEK, So Long STDY

20:52 EDT 30 Apr 2018 | RTTNews

Steadymed Ltd. (STDY) gained 77.36% on Monday, following news of its acquisition by United Therapeutics Corp. (UTHR).

More From BioPortfolio on "HTBX Gains Momentum, DOVA Faces FDA In May, No Stopping CHEK, So Long STDY"